(Albany, United States) As per DelveInsight’s assessment, globally, the TCR Therapy pipeline constitutes 25+ key companies continuously working towards developing 25+ TCR Therapy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the TCR Therapy Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, TCR Therapy NDA approvals (if any), and product development activities comprising the technology, TCR Therapy collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the TCR Therapy pipeline treatment landscape of the report, click here @ TCR Therapy Pipeline Outlook

 

Key Takeaways from the TCR Therapy Pipeline Report

• DelveInsight’s TCR Therapy Pipeline analysis depicts a robust space with 25+ active players working to develop 25+ pipeline treatment therapies.
• The leading TCR Therapy Companies working in the market include T-Cure, BioNTech, TScan therapeutics, Adaptimmune, TCR2 Therapeutics, Immatics N.V., Anocca AB, Gritstone, LION TCR, MediGene AG, Adaptive Biotechnologies, Cell Medica Ltd, Bellicum Pharmaceuticals, Takara Bio, Guangzhou FineImmune Biotechnology, Immatics US, Inc., Lonza Walkersville, Inc., PACT Pharma, Inc., Bluebird Bio, T-knife Therapeutics, GlaxoSmithKline, Eureka Therapeutics, and others
• Promising TCR Therapy Pipeline Therapies in the various stages of development include Rimiducid, Interleukin-2, tumor-specific TCR-T cells, VX-121/TEZ/D-IVA, ELX/TEZ/IVA, Cyclophosphamide, Fludarabine, KSH01 injection, Cyclophosphamide Capsules, and others
• On February 2023. Xinqiao Hospital of Chongqing announced a study of phase 1 & 2 clinical trials for EBV-specific TCR-T cell with anti-PD1 auto-secreted element. Epstein-Barr virus (EBV) infections is known to be a high-risk factor to induce nasopharyngeal cancers. To date, EBV-related head and neck squamous cell carcinoma (HNSCC) is still a major concern in east Asia, especially in China. Concurrent therapies for HNSCC have limited response rate and high chance of relapse.
• On June 2023, Vertex Pharmaceuticals announced a study of 3 of clinical trials for VX-121/TEZ/D-IVA, The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are homozygous for F508del, heterozygous for F508del and a gating (F/G) or residual function (F/RF) mutation, or have at least 1 other TCR CF transmembrane conductance regulator (CFTR) gene mutation and no F508del mutation. 

 

TCR Therapy Overview

T-cell receptor (TCR)-based adoptive therapy employs genetically modified lymphocytes that are directed against specific tumor markers. This therapeutic modality requires a structured and integrated process that involves patient screening (e.g., for HLA-A*02:01 and specific tumor targets), leukapheresis, generation of transduced TCR product, lymphodepletion, and infusion of the TCR-based adoptive therapy.

 

To explore more information on the latest breakthroughs in the TCR Therapy Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/tcr-therapy-pipeline-insight

 

TCR Therapy Emerging Drugs Profile

• GSK3377794: GlaxoSmithKline
• BPX-701: Bellicum Pharmaceuticals
• MDG1011: Medigene AG

 

TCR Therapy Pipeline Therapeutics Assessment

There are approx. 25+ key companies which are developing the therapies for TCR Therapy. The TCR Therapy companies which have their TCR Therapy drug candidates in the most advanced stage, i.e. Phase II include, GlaxoSmithKline.

 

Request a sample and discover the recent advances in TCR Therapy Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/tcr-therapy-pipeline-insight

 

TCR Therapy Drugs and Companies

• Cyclophosphamide: Takara Bio Inc
• Fludarabine: TCR Cure BioPharma Ltd
• TAEST16001: Zhujiang Hospital/ Xiangxue Pharmaceutical
• nivolumab (Opdivo®): Immatics US Inc
• Blinatumomab: Amgen

TCR Therapy Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the TCR Therapy Therapeutics Market include-

T-Cure, BioNTech, TScan therapeutics, Adaptimmune, TCR2 Therapeutics, Immatics N.V., Anocca AB, Gritstone, LION TCR, MediGene AG, Adaptive Biotechnologies, Cell Medica Ltd, Bellicum Pharmaceuticals, Takara Bio, Guangzhou FineImmune Biotechnology, Immatics US, Inc., Lonza Walkersville, Inc., PACT Pharma, Inc., Bluebird Bio, T-knife Therapeutics, GlaxoSmithKline, Eureka Therapeutics, and others.

 

Dive deep into rich insights for drugs for TCR Therapy Pipeline, click here for TCR Therapy Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/tcr-therapy-pipeline-insight

 

Scope of the TCR Therapy Pipeline Report

• Coverage- Global
• TCR Therapy Companies- T-Cure, BioNTech, TScan therapeutics, Adaptimmune, TCR2 Therapeutics, Immatics N.V., Anocca AB, Gritstone, LION TCR, MediGene AG, Adaptive Biotechnologies, Cell Medica Ltd, Bellicum Pharmaceuticals, Takara Bio, Guangzhou FineImmune Biotechnology, Immatics US, Inc., Lonza Walkersville, Inc., PACT Pharma, Inc., Bluebird Bio, T-knife Therapeutics, GlaxoSmithKline, Eureka Therapeutics, and others.
• TCR Therapy Therapies- Rimiducid, Interleukin-2, tumor-specific TCR-T cells, VX-121/TEZ/D-IVA, ELX/TEZ/IVA, Cyclophosphamide, Fludarabine, KSH01 injection, Cyclophosphamide Capsules, and others.
• TCR Therapy Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on TCR Therapy Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/tcr-therapy-pipeline-insight

 

Table of Content

1. Introduction
2. Executive Summary
3. TCR Therapy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Mid Stage Products (Phase II)
7. GSK3377794: GlaxoSmithKline
8. Drug profiles in the detailed report…..
9. Early Stage Products (Phase I/II)
10. BPX-701: Bellicum Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Preclinical stage products
13. MCC1 TCR: Bluebird Bio
14. Drug profiles in the detailed report…..
15. Inactive Products
16. TCR Therapy Key Companies
17. TCR Therapy Key Products
18. TCR Therapy- Unmet Needs
19. TCR Therapy- Market Drivers and Barriers
20. TCR Therapy- Future Perspectives and Conclusion
21. TCR Therapy Analyst Views
22. TCR Therapy Key Companies
23. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services